ArticleThe oncologist2010

Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.

Richard D PressPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.